powerpoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ats/idsa...
TRANSCRIPT
![Page 1: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/1.jpg)
![Page 2: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/2.jpg)
![Page 3: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/3.jpg)
![Page 4: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/4.jpg)
![Page 5: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/5.jpg)
![Page 6: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/6.jpg)
![Page 7: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/7.jpg)
![Page 8: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/8.jpg)
![Page 9: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/9.jpg)
![Page 10: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/10.jpg)
![Page 11: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/11.jpg)
![Page 12: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/12.jpg)
![Page 13: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/13.jpg)
![Page 14: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/14.jpg)
![Page 15: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/15.jpg)
![Page 16: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/16.jpg)
![Page 17: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/17.jpg)
Subgroup OR for mortality per hour until antibiotics
Absolute increase of mortality per hour until antibiotics
OR 95% CI p Percent 95% CI p
Sepsis 1.09 1.00-1.19 0.046 0.3% 0.01-0.6% 0.04
Severe sepsis
1.07 1.01-1.24 0.014 0.4% 0.1-0.8% 0.02
Septic shock
1.14 1.06-1.23 0.001 1.8% 0.8-3.0% 0.001
![Page 18: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/18.jpg)
![Page 19: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/19.jpg)
![Page 20: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/20.jpg)
![Page 21: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/21.jpg)
![Page 22: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/22.jpg)
![Page 23: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/23.jpg)
![Page 24: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/24.jpg)
![Page 25: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/25.jpg)
![Page 26: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/26.jpg)
Rationale Antimicrobial coverage
Example
Broader coverage Do not overlap Metronidazole + cephalosporins
Reduce the risk of inappropriate ABx
Overlap PTZ + FQ/AG
Additive/synergistic effect
Overlap Ampicillin + AG for enterococci
Reduce the risk of emergence of resistance
Overlap TuberculosisHIV
Immunomodulatingeffect
Irrelevant Macrolides
![Page 27: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/27.jpg)
2016 ATS/IDSA HAP/VAP Guidelines
Vancomycin
Linezolid
Piperacillin-tazobactam
Cefepime orCeftazidime
Carbapenems
Aztreonam
FQ
AG
Polymyxins
MRSA Activity(if risk present)
Anti-pseudomonalBeta-lactams
Anti-pseudomonalNon-beta-lactams
![Page 28: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/28.jpg)
Huh K et al. Diagn Microbiol Infect Dis 2013;76:477-82KARSNet, 2015-16 (unpublished data)
12.921.8
9.5
31.8
4.3
51.6
0
10
20
30
40
50
60
70
80
90
100
P. aeruginosa (2008) P. aeruginosa (2015-16) A. baumannii (2015-16)
![Page 29: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/29.jpg)
![Page 30: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/30.jpg)
![Page 31: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/31.jpg)
![Page 32: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/32.jpg)
![Page 33: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/33.jpg)
![Page 34: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/34.jpg)
![Page 35: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/35.jpg)
![Page 36: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/36.jpg)
Vardakas KZ et al. Int J Antimicrob Agent. 2018;51:535-547
Monotherapy betterCombination better
![Page 37: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/37.jpg)
• Pneumonia or bacteremia: 87%
• A. baumannii 77%
![Page 38: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/38.jpg)
2015 AHA Guidelines for Infective Endocarditis
2011 IDSA Guidelines for MRSA Infections
![Page 39: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/39.jpg)
Thwaites GE et al. Lancet. 2018;391(10121):668-678
![Page 40: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/40.jpg)
![Page 41: PowerPoint 프레젠테이션plan.medone.co.kr/115_accc2019/file/huh_kyungmin.pdf · 2016 ATS/IDSA HAP/VAP Guidelines Vancomycin Linezolid Piperacillin-tazobactam Cefepime or Ceftazidime](https://reader035.vdocument.in/reader035/viewer/2022081406/5f0eb7a77e708231d4409830/html5/thumbnails/41.jpg)